Lead Compass Investment

Wellmarker Bio is engaged in the development of innovative cancer therapies, focusing on biomarker-based drugs tailored to address unmet medical needs in various cancers, including colon, lung, and liver cancer. The company leverages its extensive research expertise and a dedicated drug development institute, which encompasses departments for target discovery, drug discovery, medicinal chemistry, and CMC. By utilizing R&D infrastructure from Asan Medical Center in Seoul, South Korea, Wellmarker Bio aims to create first-in-class drugs that can effectively overcome resistance to existing treatments. The company's approach highlights its commitment to advancing cancer care and improving patient outcomes through targeted therapeutic innovations.

OxVax Ltd. is a spin-out company from the University of Oxford dedicated to developing an advanced dendritic cell vaccine platform aimed at treating solid tumor cancers. The company's innovative technology utilizes induced pluripotent stem cells (iPSC) to generate CD141+ dendritic cells, a unique subset that presents promising properties for cancer immunotherapy. This approach seeks to provide effective treatment options for patients with intractable cancers, leveraging the potential of dendritic cells to enhance the immune response against tumors.